A number of oral therapies are in a late stage of development for MS (Table 2). In addition to cladribine tablets, for which key data are reviewed below, oral therapies undergoing investigation in ...

Cladribine is rapidly absorbed with maximum concentration reached 30–50 min after oral administration and 0–20% bound to plasma protein. The half-life varies from 5.6 to 7.6 h and 18.4 to 19.7 ...

There is growing clinical evidence that aHSCT can treat RRMS more effectively than DMTs. However, as most data is registry-based and previous trials did not directly compare aHSCT with the most ...

“Due to the small number of cases in pregnancies with cladribine, teriflunomide and alemtuzumab exposure, we are unable to draw any definite conclusions about rare events such as congenital ...